Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TEMIS Acquires i3 Analytics

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
TEMIS complements leading-edge Luxid® semantic content enrichment platform with best-in-class data analytics and visualization capabilities.

TEMIS has announced that they have acquired the US-based i3 Analytics, a provider of advanced data analytics and visualization technologies, for an undisclosed amount.

Founded in 2011 and employing former NIH (National Institutes of Health) engineers, i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.

Providing customers with tailor-made, relevant and intuitive visualization maps, the i3 Analytics' Biopharma Navigator enables Life Sciences professionals to work faster, provide critical information to their peers, and make fast and informed clinical, regulatory, and business decisions.

Awarded "Best Semantic Technology Solution" in January 2013 by the Software and Information Industry Association (SIIA) for its flagship platform Luxid®, TEMIS has developed an in-depth expertise serving the information extraction and semantic enrichment needs of a varied range of industries, including Defence, Publishing & Media, as well as Life Sciences, where demand for easy-to-use, intuitive visualization and analytics tools has been growing in step with the exponential growth of available unstructured content.

This acquisition reinforces TEMIS' commitment and capabilities to serving its customers by strengthening its product range with a complementary SaaS Analytics and Discovery offering and expanding its know-how with the integration of a team of former NIH engineers.

The acquisition will also enable TEMIS to accelerate its penetration into new application areas in Life Sciences.

"The acquisition of i3 Analytics demonstrates our commitment to the Life Sciences market", said Eric Brégand, CEO of TEMIS.

Brégand continued, "This transaction creates a best-in-class offering for our Life Sciences customers, based on the winning combination of deep computational linguistics expertise and leading-edge data visualization know-how. And we will be transposing the solution to other verticals where data analytics and information visualization are also becoming critical."

Moving forward, and with a focus on maintaining its commitment to simplicity and innovation, TEMIS will integrate the SaaS Biopharma Navigator into its Luxid® product line and make it available for other application segments.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bloomberg BNA Selects TEMIS for Content Categorization and Enrichment
Leading legal publisher applying powerful Luxid® Content Enrichment solution to vast archive.
Wednesday, April 17, 2013
TEMIS Named SIIA CODiE Award Finalist for Best Semantic Technology Solution
Luxid® content enrichment platform earns prestigious content industry recognition.
Friday, January 11, 2013
TEMIS Selected to Provide Semantic Indexing and Content Enrichment Solution for Gannett
Gannett to deploy Luxid® across the company’s digital properties enterprise-wide, including USATODAY.COM.
Thursday, April 05, 2012
HCPro Partnering with TEMIS to Boost Power of New Compliance Products
HCPro adds TEMIS semantic content enrichment capabilities.
Monday, December 19, 2011
Temis Luxid® standardizes on UIMA
Temis’ UIMA support enables Organizations to integrate Luxid® into their Enterprise Content Management and Information Retrieval applications.
Thursday, October 05, 2006
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Real-Time Imaging of Embryo Development Could Pave the Way
Researchers at IMCB have developed advanced microscopy technologies to monitor embryo development for more effective human reproduction therapies.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!